Every cancer specimen is genetically unique, yet all share common traits like uncontrolled division and co-opting normal cell survival mechanisms. The key to treatment is finding pathways that are different enough from normal cells to target and exploit.

While revolutionary for liquid tumors, CAR-T cells struggle to attack solid tumors. The tumor's 'microenvironment'—a complex ecosystem of blood vessels, immune cells, and supportive structures—acts as a physical and biological barrier that prevents the engineered T-cells from reaching their target.

Traditional 2D cell cultures can be misleading. Advanced 3D models, by reconstituting the tumor microenvironment with stromal cells, can uncover mechanisms of drug resistance (e.g., to ADCs) that are completely invisible in simpler systems, providing more clinically relevant data.

A specific macrophage population expressing SPP1 serves as a novel biomarker for true, tissue-level hypoxia. This allows researchers to distinguish drug-induced hypoxia from the 'pseudo-hypoxic' state caused by VHL deficiency, which has been a major challenge in studying RCC biology and treatment response.

The traditional ABC/GCB classification for DLBCL is flawed. Single-cell sequencing reveals that tumors classified as one type via bulk analysis contain malignant cells of the other subtype. This underlying heterogeneity explains why the distinction is an imperfect predictor and will be replaced by more sophisticated biomarkers like T-cell exhaustion signatures.

Metastasis is not merely cancer cells breaking away. Research shows it is often driven by the body's own immune cells (macrophages) fusing with tumor stem cells. This creates a new hybrid cell that inherits the macrophage's ability to travel throughout the body.

A tumor can be viewed as an evolving system within the body's environment. It progresses from stage to stage by "ratcheting up" its functional information—its ability to survive and grow. This evolutionary framework could inspire novel cancer treatments.

Unlike AML, myelofibrosis is not cell-autonomous. Malignant cells damage the bone marrow and spleen via cytokines. This chronic environmental damage explains slow recovery post-transplant and highlights the need for therapies that address this influence, not just the cancer cells themselves.

Recent findings from the AACR conference show a trend away from discovering new T-cell function-promoting targets. Instead, researchers are focusing on novel targets that alter the tumor microenvironment, such as breaking down collagen or repolarizing immune cells, to make existing therapies like checkpoint inhibitors more effective.